538 results on '"Urba, Walter J."'
Search Results
102. Abrogation of the Hematological and Biological Activities of the Interleukin-3/Granulocyte-Macrophage Colony-Stimulating Factor Fusion Protein PIXY321 by Neutralizing Anti-PIXY321 Antibodies in Cancer Patients Receiving High-Dose Carboplatin
103. Primary Solid Tumors of the Heart
104. A pilot study of an autologous tumor-derived autophagosome vaccine with docetaxel in patients with stage IV non-small cell lung cancer
105. Abstract 37: Anti-OX40 (MEDI6469) prior to definitive surgical resection in patients with head and neck squamous cell carcinoma
106. Abstract 38: Development of a DC-targeted microvesicle vaccine to intercept the progression of oral preneoplasia to cancer
107. Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab
108. Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40
109. Multiparametric immune profiling in HPV– oral squamous cell cancer
110. Abstract 2988: Immunogenomic analyses of tumor cells and microenvironment in patients with advanced melanoma before and after treatment with nivolumab
111. Abstract CT073: Immunomodulatory effects of nivolumab and ipilimumab in combination or nivolumab monotherapy in advanced melanoma patients: CheckMate 038
112. Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody
113. A phase I clinical trial of flavone-8-acetic acid in combination with interleukin 2
114. Autophagy-assisted antigen cross-presentation
115. Combinational Immunotherapy with Allo-DRibble Vaccines and Anti-OX40 Co-Stimulation Leads to Generation of Cross-Reactive Effector T Cells and Tumor Regression
116. Unmasking PD-1 Resistance by Next-Generation Sequencing
117. Glimpse into the future: harnessing autophagy to promote anti-tumor immunity with the DRibbles vaccine
118. Appearance of neuropeptides in ascitic fluid after peritoneal therapy with interleukin-2 and lymphokine-activated killer cells for intraabdominal malignancy
119. H-2-linked recessiveIr gene regulation of high antibody responsiveness to TNP hapten conjugated to autogenous albumin
120. Hierarchy ofH-2 haplotypes governs inheritance of immune responsiveness to TNP-MSA
121. Serum Immunoregulatory Proteins as Predictors of Overall Survival of Metastatic Melanoma Patients Treated with Ipilimumab
122. Multispectral imaging of formalin-fixed tissue predicts ability to generate tumor-infiltrating lymphocytes from melanoma
123. Abstract 2855: Immunomodulatory activity of nivolumab monotherapy in patients with advanced melanoma
124. 29th Annual meeting of the Society for Immunotherapy of Cancer (SITC)
125. Abstract P5-01-12: Breast specific gamma imaging (BSGI) and breast magnetic resonance imaging (MRI): Comparison of sensitivity and specificity in women prior to breast biopsy with BIRADS 4 or 5 finding on mammography in a community setting
126. Effect of Carboxyamidotriazole Orotate, a Modulator of Calcium-Dependent Signaling Pathways, on Advanced Solid Tumors
127. Undefined-Antigen Vaccines
128. Profiling of suppressive immune subsets in metastasis negative and positive sentinel lymph nodes from patients with HER2- breast cancer
129. Comparison of proteomic and genomic analyses of vaccine cell lines shows men receiving prostate gvax immunotherapy develop increased humoral responses to common cell line proteins relative to mutated proteins
130. Evaluation of circulating tumor cell gene expression profiles before and following combination immunotherapy for advanced prostate cancer
131. Characterizing the immunoprofile and endogenous immune response to squamous cell carcinomas of the head and neck to guide development of effective immunotherapy strategies
132. Preliminary analysis of immune responses in patients enrolled in a Phase II trial of Cyclophosphamide with Allogenic DRibble Vaccine Alone (DPV-001) or with GM-CSF or Imiquimod for adjuvant treatment of Stage IIIA or IIIB NSCLC
133. At the Bench: Adoptive cell therapy for melanoma
134. Cross-presentation of viral antigens in dribbles leads to efficient activation of virus-specific human memory t cells
135. Durable responses and reversible toxicity of high-dose interleukin-2 treatment of melanoma and renal cancer in a Community Hospital Biotherapy Program
136. Resistance to recombinant interferon alfa-2a in hairy-cell leukemia associated with neutralizing anti-interferon antibodies
137. OX40 Is a Potent Immune-Stimulating Target in Late-Stage Cancer Patients
138. A Phase II Study of Bevacizumab and High-dose Interleukin-2 in Patients With Metastatic Renal Cell Carcinoma
139. Developing an immunotherapy strategy for the effective treatment of patients with squamous cell carcinoma of the head and neck
140. DPV-001 an autophagosome-enriched cancer vaccine in phase II clinical trials contains 25 putative cancer antigens, DAMPS, HSPS and agonists for TLR 2, 3, 4, 7 and 9
141. Novel strategy to monitor apparent tumor-specific T cells in patients with cancer
142. Melanoma: More Answers, More Questions
143. The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment
144. Metastatic melanoma can be cured: advances in immunotherapy and targeted approaches
145. Phase 1 Study of Stereotactic Body Radiotherapy and Interleukin-2—Tumor and Immunological Responses
146. Tumor-Derived Autophagosome Vaccine: Mechanism of Cross-Presentation and Therapeutic Efficacy
147. Multiple Vaccinations
148. The iSBTc/SITC primer on tumor immunology and biological therapy of cancer: a summary of the 2010 program
149. Signaling Through OX40 Enhances Antitumor Immunity
150. CD122 + CD8 + Treg suppress vaccine‐induced antitumor immune responses in lymphodepleted mice
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.